Moderna (MRNA) has been incredibly explosive for us.

The first time we highlighted opportunity, the stock traded at $72 on Oct. 20.  At the moment, it’s up to $171.92 in pre-market, and we still believe it could rally to $200.

For one, “This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID-19 disease. We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death,” Moderna CEO Stephane Bancel said.

Two, the company could see emergency use authorization shortly after its Dec. 17 meeting with the US FDA.  While the specifics of how long the US FDA will take to make its decision are not clear, the company says it could hear back between December 18 and 20.

However, MRNA isn’t the only stock worth watching.

Pfizer and BioNTech are still racing higher after the US FDA said their vaccine was safe and effective, potentially paving the way for emergency use approval.

As noted by The Wall Street Journal, “the FDA noted that the two-dose vaccine provided benefits even after just the first injection—cutting the risk of getting Covid-19 by about half. The vaccine was found to be 95% effective after the second dose, three weeks later.  FDA scientists also found that the vaccine was effective in reducing the risk of confirmed severe disease after the first dose, an important finding as some health experts were concerned Covid-19 vaccines would protect against only mild to moderate disease.”

While there are plenty more vaccine opportunities, these three have immediate catalysts.